Welcome to our dedicated page for Radiopharm Theranostics SEC filings (Ticker: RADX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Radiopharm Theranostics Limited (RADX) SEC filings page provides access to the company’s U.S. regulatory disclosures as a foreign private issuer. Radiopharm files reports on Form 20‑F and Form 6‑K under the Securities Exchange Act of 1934, often furnishing Australian Securities Exchange announcements as exhibits for U.S. investors.
Recent Form 6‑K filings reference clinical and corporate milestones, such as interim Phase 2b data for 18F‑RAD101 in brain metastases, progress in Phase 1 trials of 177Lu‑RAD202 and 177Lu‑RAD204, ethics approval for the RAD402 prostate cancer trial, and U.S. FDA IND clearance for RV‑01 (Betabart). Other 6‑K submissions include notices of annual and extraordinary general meetings, results of shareholder votes, director interest notices, quarterly cash flow reports and presentations to investors.
Through this page, users can review how Radiopharm reports on its radiopharmaceutical pipeline, including imaging and therapeutic candidates targeting FASN, HER2, PD‑L1, αvβ6‑integrin, KLK3 and B7H3. Filings may also reference capital raisings, cash runway commentary and supply agreements for key radioisotopes used in clinical trials.
Stock Titan enhances these documents with AI-powered summaries that highlight the main points of lengthy filings, helping readers quickly understand trial updates, board and governance changes, and financing terms. Real‑time ingestion from EDGAR means new 6‑K and 20‑F submissions appear promptly, while integrated views of director interest notices and meeting results help track governance and potential insider‑related changes without manually reading every exhibit.
Radiopharm Theranostics Limited completed a registered direct offering of 1,281,646 ADSs, each representing 300 ordinary shares, at US$3.16 per ADS, raising aggregate gross proceeds of approximately US$4.1 million before fees. In a concurrent private placement, it agreed to issue investors unregistered warrants to purchase up to 1,281,646 ADSs, exercisable at US$3.79 per ADS and expiring on July 31, 2029, following shareholder approval of the underlying ordinary shares.
The company also received firm commitments of approximately A$6.7 million (US$4.7 million) from Australian institutional and professional investors in an Australian Placement, where issuance of 40.0 million ordinary shares for A$0.6 million will be subject to shareholder approval under ASX rules. A Share Purchase Plan for shareholders in Australia and New Zealand may raise up to an additional A$6 million (US$4.2 million). Under the Australian Placement and the Share Purchase Plan, participants are expected to receive one option per new ordinary share, with an exercise price of A$0.018 and expiry on July 31, 2029, subject to shareholder approval. Proceeds are intended to fund preparation for the RAD101 registrational Phase 3 study, completion of RAD204 dose escalation, advancement of RAD202, RAD402 and RV01 programs, strategic partnering initiatives, and general corporate purposes.
Radiopharm Theranostics Limited issued 384,493,800 new RAD ordinary fully paid shares for cash at AUD 0.01500000 per share, to be quoted on ASX from 28 July 2026 as part of a placement previously outlined in an Appendix 3B.
The company states that further securities remain to be issued under that transaction, including 448,839,531 additional ordinary shares, 448,839,531 options expiring 31-Jul-2029 with an exercise price of 0.018, and ADR warrants of 64,082 and 1,281,646 expiring 31-Jul-2029 with exercise prices of USD 3.95 and USD 3.79.
Following quotation of the new shares, RAD ordinary fully paid shares on issue will total 3,928,709,960, alongside multiple quoted option series such as RADAN options, which number 387,179,525 and have various expiries and exercise prices.
Radiopharm Theranostics Limited is raising capital through a US registered direct offering and concurrent Australian transactions. The company agreed to sell 1,281,646 American Depositary Shares (ADSs), representing 384,493,800 ordinary shares, at US$3.16 per ADS to raise approximately US$4.1 million in gross proceeds.
In a concurrent private placement, investors will receive unregistered warrants to purchase up to 1,281,646 ADSs at an exercise price of US$3.79 per ADS, expiring on July 31, 2029, exercisable after shareholder approval. Separately, Australian institutional and professional investors have provided firm commitments for approximately A$6.7 million in a private placement, and a Share Purchase Plan could raise up to an additional A$6 million, both with one option (exercise price A$0.018, expiring July 31, 2029) for every new ordinary share subscribed, subject to shareholder approval.
The company expects to seek the necessary approvals at an extraordinary general meeting on or about September 11, 2026, and intends to use proceeds to advance the RAD101 registrational study, progress multiple therapeutic programs, support strategic partnering initiatives, and for general corporate purposes.
Radiopharm Theranostics Limited is conducting a primary offering of 1,281,646 American Depositary Shares (ADSs), representing 384,493,800 ordinary shares, at $3.16 per ADS, for gross proceeds of $4,050,001.36. Net proceeds are estimated at about US$3.3 million after placement agent fees and expenses.
In a concurrent private placement, investors receive unregistered Warrants to purchase up to 1,281,646 ADSs at an exercise price of $3.79 per ADS, expiring July 31, 2029, contingent on shareholder approval. Placement agent H.C. Wainwright earns a 7.0% cash fee plus expenses and Warrants to purchase 64,082 ADSs at $3.95 per ADS.
Proceeds are intended to fund preparation and readiness for the RAD101 registrational Phase 3 study, completion of RAD204 dose escalation, advancement of RAD202, RAD402 and RV01 programs, strategic partnering initiatives and general corporate purposes. An additional Australian private placement of A$6.7 million and a share purchase plan of up to A$6 million are also planned.
Radiopharm Theranostics Limited is raising capital through concurrent U.S. and Australian transactions. The company entered a Securities Purchase Agreement with certain U.S. accredited institutional investors for a registered direct offering of 1,281,646 ADSs, each representing 300 ordinary shares (384,493,800 ordinary shares), at US$3.16 per ADS to raise aggregate gross proceeds of approximately US$4.1 million before fees. In a concurrent private placement, Radiopharm will issue unregistered warrants to purchase up to 1,281,646 ADSs, exercisable on or after shareholder approval of the underlying ordinary shares, with an exercise price of US$3.79 per ADS and expiry on July 31, 2029. Closing is expected on or about July 28, 2026, with H.C. Wainwright & Co. as exclusive U.S. placement agent.
In Australia, the company has firm commitments from institutional and professional investors for approximately A$6.7 million (US$4.7 million) in a private placement, with the issuance of 40.0 million ordinary shares for A$0.6 million (US$0.4 million) subject to shareholder approval under ASX listing rules. Radiopharm also plans a Share Purchase Plan for eligible Australian and New Zealand shareholders to raise up to an additional A$6 million (US$4.2 million), also subject to approval. Under both the Australian Placement and Share Purchase Plan, investors are expected to receive one option per new share, with an exercise price of A$0.018 and expiry on July 31, 2029, subject to shareholder approval and ASX quotation. Approvals are expected to be sought at an extraordinary general meeting on or about September 11, 2026. The company intends to use the proceeds to commence its RAD101 registrational study, advance multiple therapeutic programs through key clinical milestones, support strategic partnering initiatives, and for working capital and general corporate purposes.
Radiopharm Theranostics Limited is amending its existing prospectus supplement to update the terms of an at-the-market equity program for its American Depositary Shares, or ADSs. Under this updated prospectus supplement, the company may sell ADSs having an aggregate offering price of up to $9,300,000 from time to time through or to Leerink Partners LLC, acting as sales agent or principal, under a December 16, 2025 sales agreement. Each ADS represents 300 ordinary shares. Leerink Partners will use commercially reasonable efforts to place the ADSs in transactions deemed an “at the market” offering and will receive a 3.0% commission on the gross sales price per ADS. As of July 7, 2026, the company’s public float was approximately US$40,165,592, and sales are subject to the one-third public float limitation under General Instruction I.B.5 of Form F-3. The ADSs trade on Nasdaq under the symbol RADX, where the last reported sale price on July 21, 2026 was $4.29 per ADS.
Radiopharm Theranostics Limited reported encouraging clinical data for two key radiopharmaceutical programs. In an ongoing Phase 1 trial of RAD204, a PD-L1-targeted lutetium-177 nanobody for advanced solid tumors post-immunotherapy, the first patient in cohort 3 at the highest dose level #3 (90 mCi) achieved a RECIST-confirmed durable Partial Response, remaining progression-free for beyond seven months. A second patient in the same cohort remains on treatment with early tumor shrinkage, and RAD204 has been generally well-tolerated with no dose-limiting toxicities across dosing cohorts.
In a Phase 2b imaging trial of RAD101 for suspected recurrent brain metastases after radiotherapy, PET imaging with 18F-RAD101 achieved 93% concordance with MRI across all evaluable lesions, meeting the primary endpoint. Among 14 patients with six-month follow-up and/or biopsy, preliminary sensitivity was 86% (12/14), with specificity data expected in Q4 2026. Radiopharm plans to advance RAD101 into a U.S. Phase 3 pivotal trial in Q4 2026. RAD101 holds U.S. FDA Fast Track Designation, and the brain metastases imaging market is estimated at approximately $600+m, with more than 300,000 patients diagnosed annually in the U.S. with cerebral metastases.
Radiopharm Theranostics Limited reports receiving an Australian R&D tax refund for the 2025 financial year totaling A$5,885,131, including A$104,475 of interest. This payment comes from the Australian Government’s R&D tax incentive program, which offers a refundable tax offset of up to 43.5% for eligible activities.
The company states that this non-dilutive funding will support continued development of its radiopharmaceutical portfolio for diagnostic and therapeutic use in oncology, where it is running one Phase 2 and five Phase 1 clinical trials across several solid tumor types.
Theranostics Limited reported changes to its capital structure involving lapses and new grants of unquoted options. Several tranches of RADAN and RADAJ options, totaling 8,540,000, 17,305,743, 10,666,666 and 712,301 respectively, ceased on dates in 2025 and early 2026 after conditions for exercise were not satisfied, with no consideration paid.
The company also issued 2,666,666 new RADAN options on 30 June 2026 under an employee incentive scheme, ranking equally with existing RADAN options. Following these changes, issued capital includes 3,544,216,160 RAD ordinary fully paid shares and 423,691,934 RADAN options on issue, alongside other option series with various expiries and exercise prices.
Theranostics Limited reported that 505,598 unquoted RADAN options expired on 31 May 2026 without being exercised or converted, meaning these potential shares will no longer be issued. No consideration was paid in connection with the cessation.
After this change, the company reports 3,544,216,160 RAD ordinary fully paid shares on issue, alongside multiple series of outstanding options, including 421,025,268 RADAN options and several other option classes with varying expiry dates and exercise prices.